Targeted protein degradation: a new pharmacology paradigm?

Traditional drug development focuses on targeting proteins with a defined binding pocket or active site to regulate protein activity. These strategies have exploited only around 400 of the 4000...
Learn More

What Happens to Pharma Valuations as Interest Rates Rise?

Everyone familiar with the risk-adjusted net present value method (rNPV) knows automatically that valuations decrease as the discount rate increases. This is indeed a fundamental tenet of the...
Learn More

Targeted Radiotherapy: The Comeback Kid of Cancer Treatment?

The notion that a systemically administered source of radiation can be usefully directed towards a tumor has been exploited since the 1940s, when radioiodine was introduced as a treatment for thyroid...
Learn More

Light Due Diligence: A Contradiction in Terms?

Alacrita has established itself as an industry specialist in due diligence (DD), conducting over 25 DD assignments per year, across therapeutic areas and technologies. Sometimes a prospective clients...
Learn More

Could COVID-19 be a catalyst for virtualizing clinical trials?

The virtualization of clinical trials has long been technically feasible, but cultural and regulatory barriers have prevented implementation. With over 1200 clinical trials worldwide being...
Learn More

Adapting to Our “New” Virtual Reality in Biotech

In the current crisis, working virtually is now a reality for many. The preparedness for this varies greatly. For some it’s business as usual, for others “going virtual” simply hasn’t been feasible,...
Learn More

Pipeline asset valuation: garbage in – garbage out

Methods of valuing pharmaceutical development-stage assets have been a perennial talking point for decades, and the advantages and disadvantages of each have been covered in numerous publications....
Learn More

COVID-19: a catalyst for anti-infective investing?

There has been a persistent call from early stage innovators to shine a spotlight on building anti-infective defenses in light of the looming crisis of antimicrobial resistance (AMR). Unfortunately,...
Learn More

The risk-reward balance in drug repurposing

Does drug repurposing overcome the hurdles and pitfalls in drug development? Having conducted several recent due diligence exercises in the repurposing space, we discuss the gems and the hidden...
Learn More

Gene Therapy: Suspending Vector Immunity and Facilitating Re-Dosing?

Vector immunity is currently a major limiting factor in gene therapy. In the first place, patients with pre-existing immunity may either be ineligible for treatment or may require extremely high...
Learn More

Pharmaceutical Patents: an overview

Protecting new treatments and innovations is critical for drug developers. In this article, we provide of an overview of the history of patents, what a patent is, the general process to obtain one...
Learn More

Moving beyond cancer: CAR-T therapy takes on autoimmune disease

It’s not untypical for an emerging cancer treatments to be dubbed “revolutionary” or “game-changing”, but stepping beyond cliché, chimeric antigen receptor T-cell (“CAR-T”) therapy can rightly be...
Learn More
Previous
1 2 3 4 5 ... 6
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-24 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.